Target Therapeutics (US) gets 510(k) for intracranial coil:
This article was originally published in Clinica
Executive Summary
Target Therapeutics (US) has received FDA clearance to market the Guglielmi detachable coil for intracranial aneurysms. The soft platinum alloy microcoil is intended for use in inoperable or surgical high-risk stroke patients. The coil is delivered using Target's Tracker microcatheter and released electrically. Nearly 40,000 intracranial aneurysms are diagnosed in the US every year and about 25% of these are deemed either inoperable or high-risk for surgical repair.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.